ALPHAMAB ONCOLOGY |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.84 HKD | -1.22% |
|
-5.10% | -27.11% |
| May. 02 | Alphamab Oncology's 2023 Loss Narrows as Revenue Rises | MT |
| Apr. 10 | Alphamab Oncology Presents Phase-I Clinical Trial Results at 2024 AACR Annual Meeting | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Compared values
| Sector | Change | 5d. change | 1st Jan change | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| ALPHAMAB ONCOLOGY | Other Biotechnology & Medical Research | -1.22% | -5.10% | -27.11% | -47.10% | - | 606M |  |  |  |
Technical Rankings Surperformance
- Stock Market
- Equities
- 9966 Stock
- Charts Alphamab Oncology
- Comparison Chart
